Cancer Vaccines and Gene Therapy (CVGT) Meeting

The Cancer Vaccines and Gene Therapy Meeting is an annual event that brings together important leaders to present and discuss the latest approaches and technologies used to develop promising anti-cancer therapeutics.  Learn how to maximize the potential of cancer immunotherapeutics  and implement strategies to ensure successful cancer vaccine development.

The 1st CVGT Meeting was held in October 2013, see the 2013 Agenda
The 2nd CVGT Meeting was held in October 2014, see the 2014 Agenda
The 3rd CVGT Meeting planned for 12 - 13 October 2015, Agenda

Presentations to date include:

Dale Haines, Alex's Lemonade Stand Foundation
Funding opportunities at Alex's Lemonade Stand Foundation for Child Cancer Research

Kimberly Kraynyak, Product Development Scientist, Inovio Pharmaceuticals
Statistical association between cellular immune responses and regression of HPV 16/18 CIN2/3 lesions; results from a phase 2b trial of VGX-3100

Andrea Facciabene, Research Assistant Professor, University of Pennsylvania
A Tumor Mitochondria Vaccine Protects Against Experimental Renal Cell Carcinoma

Agnete Fredriksen, Chief Scientific Officer, Vaccibody

Pioneering immunotherapy with targeted vaccines. Update on VB10.16 immunotherapy to treat patients with high-grade cervical lesions and the Vaccibody platform potential.

Douglas G. McNeel, Professor of Medicine, University of Wisconsin
DNA vaccines for prostate cancer treatment - understanding mechanisms of resistance

Richard Heller, Professor & Eminent Scholar, Old Dominion University
Enhanced Immunotherapy Utilizing Gene Electro Transfer to Deliver Plasmids Encoding Cytokines

Alexander Shneider, CEO/CSO CureLab Oncology
p62-SQSTM1 DNA Vaccine for Cancers and Chronic Inflammation

Gary Koski, Associate Professor, Kent State University
Th1 cytokine-induced apoptosis in breast cancer cells

Brian Czerniecki, Co-Director of the Rena Rowan Breast Center, University of Pennsylvania
Using Anti-Oncodriver Th1 Immune Responses as Prognostics and Therapeutic Tools in Breast Cancer

Suresh Kumar, Associate Director, R and D, Progenra Inc.
Targeting Ubiquitin Signaling System for Cancer Immunotherapy

Joe B. Harford,  President & CEO of SynerGene
Nanomedicines that cross the blood-brain-barrier to image and treat brain tumors

Pawel Kalinski, Director Immunotransplantation Center, University of Pittsburgh Cancer Institute

Polarized dendritic cells (DC) in cancer therapy: Vaccines, adoptive transfer of ex vivo-sensitized T cells and in situ DC polarization

Iver A Langmoen, Professor of Neurosurgery, University of Oslo
Our experience with an autologous dendritic cell vaccine against brain cancer

Daniel Powell, Director Cellular Therapy Tissue Facility, University of Pennsylvania
Therapeutic potential of targeting folate receptor beta in  solid and hematological cancers

Christian Capitini, Assistant Professor, Pediatric Hematology, Oncology & BMT, University of Wisconsin
Utility of tumor vaccines after allogeneic bone marrow transplant

Kevin Lye, VP of Medical Affairs, Northwest Biotherapeutics
DCVax®:  Novel Personalized Immune Therapies for Solid Tumors

Elizabeth Gabitzsch, Vice President Research, Etubics Corporation

Immunotherapy and combinational treatment of cancers using the Etubics Platform


The 2015 CVGT meeting will be held at The Desmond in Malvern Pennsylvania is a one-of-a-kind hotel, conveniently located in one of Pennsylvania’s most scenic and historic settings. From the moment you walk in, you’ll know why guests tell us The Desmond is the best part of traveling.  It’s a difference you can taste, whether you’re savoring fresh seafood and prime steaks in The Hunt Room, fresh Maine lobster in our seasonal Sunset Grille, or relaxing with cocktails, snacks and comfort food in our authentic English pub, the Fox and Hounds.


* Email
First Name
Last Name

* = Required Field



Northwest Biotherpeutics